Traditional steroid-based mineralocorticoid receptor antagonists (sMRAs), such as spironolactone and eplerenone, are effective in managing hypertension but are limited by side effects, including hyperkalemia, gynecomastia, and renal dysfunction, which often affect patient compliance and limit their long-term use. The gene discussed is NR3C2; the disease is Hyperkalemia.